




FIG. 1




FIG. 2




FIG. 3




FIG. 4A






FIG. 4C




FIG. 4D




FIG. 4E

Targeting Vector MAID1770





FIG. 4F



FIG. 4G






FIG. 6




FIG. 7




FIG. 8A




FIG. 8B





FIG. 8C







FIG. 8E






FIG. 9

21/31





FIG. 10

FIG. 11






FIG. 12




FIG. 13




FIG. 15A **Percent of CD8 T cells expressing hTRBV**

	TRBV-18	TRBV-19	TRBV-20	TRBV-25	TRBV-27	TRBV-28	TRBV-29
WT	0.03 ± 0.01	0.00 ± 0.00	0.00 ± 0.00	0.01 ± 0.01	0.01 ± 0.00	0.02 ± 0.02	0.01 ± 0.01
1716 HO	0.06 ± 0.03	0.01 ± 0.01	2.68 ± 0.51	1.20 ± 0.09	13.53 ± 0.71	10.07 ± 1.63	0.00 ± 0.00
1716 HO 1767 HO	0.07 ± 0.05	0.01 ± 0.01	1.89 ± 0.35	1.12 ± 0.11	6.71 ± 0.57	7.00 ± 0.65	0.00 ± 0.00

FIG. 15B **Percent of CD4 T cells expressing hTRBV**

	TRBV-18	TRBV-19	TRBV-20	TRBV-25	TRBV-27	TRBV-28	TRBV-29
WT	0.03 ± 0.02	0.0 ± 0.0	0.0 ± 0.0	0.03 ± 0.02	0.01 ± 0.0	0.02 ± 0.02	0.00 ± 0.01
1716 HO	0.05 ± 0.02	0.01 ± 0.00	2.35 ± 0.46	0.52 ± 0.04	2.88 ± 0.19	3.82 ± 0.66	0.00 ± 0.00
1716 HO 1767 HO	0.05 ± 0.03	0.01 ± 0.0	2.08 ± 0.15	0.23 ± 0.06	1.57 ± 0.18	2.59 ± 0.24	0.00 ± 0.00

FIG. 15




FIG. 16A






FIG. 16B


WT (110 TCRA mVs)




TCRA ΔV



TCRA 2 hv



TCRA 8hv



TCRA 23hv




FIG. 17




FIG. 18

31/31





FIG. 19